Human Genome Sciences and GlaxoSmithKline plc Company Profile

News Articles [ 2353 Associated News Articles listed on BioPortfolio]

Glaxo extends bid for Human Genome Sciences

GlaxoSmithKline PLC said Friday it has again extended its $2.6 billion hostile offer for shares of Human Genome Sciences Inc., its collaborator on the lupus drug Benlysta.GlaxoSmithKline of London sa...

GlaxoSmithKline ejects executives from recently acquired Human Genome Sciences

British drugmaker GlaxoSmithKline has expelled members of the executive suite, and most of the board of directors, at Rockville-based Human Genome Sciences on the same day it took control of the compa...

Glaxo extends offer for Human Genome Sciences

GlaxoSmithKline extended its $2.6 billion buyout bid Friday for Human Genome Sciences, which has rejected the offer.The offer from the British drugmaker will now expire June 29. The bid values Human...

GlaxoSmithKline wins takeover bid for Human Genome

(AP) — U.K. drug maker GlaxoSmithKline said Monday it had secured its takeover of Human Genome Sciences after agreeing to pay a higher price for the U.S. biotechnology company.

GSK agrees to buy Human Genome Sciences for US $3.6 billion

GSK is to acquire HGS for US $14.25 share in cash, equalling a transaction value of HGS at US $3.6 billion. GlaxoSmithKline has announced it has entered an agreement with Human Genome Sciences (HGS),...

Celgene Mulls Human Genome Sciences Bid

Celgene is one of two companies discussing whether to bid for Human Genome Sciences, which seeks an alternative to a hostile offer by British drugmaker GlaxoSmithKline, a source familiar with the situ...

GlaxoSmithKline $2.6 billion tender offer for Human Genome Sciences saga continues

Continuing its attempts to gain control of its development partner Human Genome Sciences (Nasdaq: HGSI), UK pharma giant GlaxoSmithKline (LSE: GSK) on Friday extended its original $13 a share - a tota...

Human Genome agrees to GlaxoSmithKline takeover

U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK's drug portfolio in crucial areas: biologic drugs a...

Drugs and Medications [ 155 Associated Drugs and Medications listed on BioPortfolio]

Primer [Derma Sciences Canada, Inc.]

Drug Facts

Primer [Derma Sciences Canada, Inc.]

Drug Facts

Phazyme [GlaxoSmithKline Consumer Healthcare LP]

Drug Facts

Mysotrol no rinse antiseptic hand cleanser [Derma Sciences]

Drug Facts

Primaderm anti-dandruff [Derma Sciences]

Drug Facts

PubMed Articles [ 1481 Associated PubMed Articles listed on BioPortfolio]

What Does a "Normal" Human Genome Look Like?

Human genome sequencing in health and disease.

Following the "finished," euchromatic, haploid human reference genome sequence, the rapid development of novel, faster, and cheaper sequencing technologies is making possible the era of personalized h...

Comprehensively identifying and characterizing the missing gene sequences in human reference genome with integrated analytic approaches.

The human reference genome is still incomplete and a number of gene sequences are missing from it. The approaches to uncover them, the reasons causing their absence and their functions are less explor...

A passion for the science of the human genome.

The complete sequencing of the human genome introduced a new knowledge base for decoding information structured in DNA sequence variation. My research is predicated on the supposition that the genome...

Human genome 10th anniversary. The human genome (patent) project.

Clinical Trials [ 1349 Associated Clinical Trials listed on BioPortfolio]

Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.

Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to assess the immunogenicity and safety of Gla...

The Healthy Elderly Longevity Cohort

With the completion of the human genome project, investigators can now explore new questions in human biology. Previously human genetics focused on highly penetrant, Mendelian traits; how...

Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix TM) in HIV Infected Females

Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. The current study is designed to evaluate the safety and immunogenicity of G...

Study of Lamotrigine 2×25 mg IR Tablets of Torrent Pharmaceuticals Limited, India and Lamictal® (Lamotrigine) 2×25 mg Tablets of GlaxoSmithKline, USA, in Healthy Human Adult Subjects, Under Fasting Conditions.

- Objective: - A randomized, open label, two treatment, two period, two sequence, single dose, crossover, bioequivalence study of Lamotrigine 2 x 25mg IR tablets of Tor...

Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule

The purpose of this study is to assess the occurrence of serious adverse events (SAEs) as well as evaluate the occurrence of solicited local and solicited general symptoms and the occurren...

Companies [ 1788 Associated Companies listed on BioPortfolio]

Human Genome Sciences and GlaxoSmithKline plc

Human Genome Sciences

The mission of Human Genome Sciences is to discover, develop, manufacture and market innovative drugs that serve patients with unmet medical needs, with a primary focus on protein and antibody drugs....

German Human Genome Project

In June 1995 Germany joined the international efforts of the Human Genome Project. The German Human Genome Project (DHGP) is funded by the German Federal Ministry of Education and Research (BMBF) and...

Human Genome Sciences, Inc. and FivePrime Therapeutics, Inc.

Human Genome Sciences, Inc.

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.